Related Experiment Video
Updated: May 4, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
20.2K
Assessing and treating cognitive impairment in schizophrenia: current and future
Chun-Yuan Lin, Guochuan E Tsai, Hsien-Yuan Lane1
1Institute of Clinical Medical Science, Medical College, China Medical University, Taichung, Taiwan, No.91 Hsueh-Shih Road, Taichung 404, Taiwan. hylane@gmail.com.
Current Pharmaceutical Design
|January 14, 2014
Summary
Treating cognitive impairment in schizophrenia remains challenging. Current pharmacological and non-pharmacological strategies show limited clinical benefits, necessitating further research into combination therapies and long-term efficacy.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Cognitive impairment is a core symptom of schizophrenia, persisting across all disease stages.
- It significantly impacts functional outcomes and quality of life for patients.
- Effective treatment for cognitive deficits is a major research focus.
Purpose of the Study:
- To review current assessment strategies for cognitive impairment in schizophrenia.
- To synthesize advances in pharmacological and non-pharmacological treatments.
- To identify promising future research directions.
Main Methods:
- Review of registered clinical trials (ClinicalTrials.gov).
- Analysis of strategies targeting neurochemical pathways (dopamine, glutamate, GABA, serotonin, acetylcholine, oxytocin).
- Evaluation of cognitive remediation therapy and combination approaches.
Main Results:
- Limited clinical benefits observed for most pro-cognitive drugs despite preclinical promise.
- Cognitive remediation therapy shows short-term benefits, but long-term effects and generalizability are unclear.
- Combination therapy integrating agents or rehabilitation shows promise.
Conclusions:
- Current treatments for schizophrenia cognitive impairment are suboptimal, often due to small sample sizes and short durations.
- Combination therapies represent a promising avenue for future treatment development.
- Further research is needed on long-term efficacy, rebound effects, and biomarkers.
More Related Videos
Related Concept Videos
01:30Negative and Cognitive Symptoms of Schizophrenia
1.1K
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
1.1K
01:26Psychosis: Goals of Pharmacotherapy
706
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
706
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:28Drug Therapy
449
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
449
01:30Dementia
687
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
687
01:17Schizophrenia
1.8K
Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those...
1.8K